Dermata Therapeutics Warrant
DRMAW
6 hedge funds and large institutions have $115K invested in Dermata Therapeutics Warrant in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
59% less capital invested
Capital invested by funds: $278K → $115K (-$163K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$13.7K |
| 2 |
VF
Virtu Financial
New York
|
+$5.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$17K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.04K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $52K | – | – | – |
|
|
EAM
2
Empery Asset Management
New York
| $28K | – | – | – |
|
|
WAM
3
Warberg Asset Management
Winnetka,
Illinois
| $16K | +$13.7K | +48,601 | +95% |
|
|
BFM
4
Boothbay Fund Management
New York
| $15K | – | – | – |
|
|
VF
5
Virtu Financial
New York
| $3K | +$5.14K | +18,171 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $1K | -$1.04K | -3,693 | -53% |
|
|
WVP
7
Worth Venture Partners
Fort Lee,
New Jersey
| – | -$17K | -40,075 | Closed |
|
DRMAW Hedge Fund Activity: Q1 2022 in Review
6 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q1 2022, worth a combined $115K — down 59% from $278K a quarter earlier.
Fund positioning in DRMAW was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Warberg Asset Management, adding an estimated $13.7K. The largest seller was Worth Venture Partners, exiting entirely with an estimated $17K sold.
- 6 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $115K of Dermata Therapeutics Warrant stock for Q1 2022, down 59% quarter-over-quarter.
- 1 fund opened new Dermata Therapeutics Warrant positions in Q1 2022 and 1 closed out, a net change of 0 holders.
- The largest Dermata Therapeutics Warrant buyer in Q1 2022 was Warberg Asset Management, an estimated $13.7K added.
- The largest Dermata Therapeutics Warrant seller in Q1 2022 was Worth Venture Partners, an estimated $17K sold.
Based on aggregated 13F filings for Q1 2022.